Cartesian Therapeutics, Inc.

NasdaqGM:RNAC Stock Report

Market Cap: US$415.8m

Cartesian Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:RNAC Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
20 Mar 25BuyUS$1,371,154Timothy SpringerIndividual89,863US$15.59
14 Jan 25BuyUS$366,354Timothy SpringerIndividual20,967US$18.00
06 Jan 25SellUS$134,036Blaine DavisIndividual7,989US$16.83
06 Jan 25SellUS$30,149Emily EnglishIndividual1,797US$16.83
06 Jan 25SellUS$42,783Chris JewellIndividual2,550US$16.83
06 Jan 25SellUS$31,542Milos MiljkovicIndividual1,880US$16.83
06 Jan 25SellUS$81,790Metin KurtogluIndividual4,875US$16.83
06 Jan 25SellUS$289,764Carsten BrunnIndividual17,271US$16.83
23 Dec 24BuyUS$965,021Timothy SpringerIndividual52,189US$19.00
18 Nov 24BuyUS$7,373,527Timothy SpringerIndividual431,940US$18.42
04 Oct 24BuyUS$4,293,545Timothy SpringerIndividual205,721US$23.93
12 Aug 24BuyUS$95,250Timothy BarabeIndividual7,500US$12.70
12 Aug 24BuyUS$101,968Timothy SpringerIndividual8,016US$12.72

Insider Trading Volume

Insider Buying: RNAC insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of RNAC?
Owner TypeNumber of SharesOwnership Percentage
Private Companies1,431,3905.53%
General Public2,414,1419.32%
Institutions7,135,20327.5%
Individual Insiders14,926,36757.6%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 379.9%.

Top Shareholders

Top 25 shareholders own 88.86% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
36.2%
Timothy Springer
9,385,399US$150.6m0.25%no data
19.5%
Murat Kalayoglu
5,057,682US$81.2m0.04%no data
9.35%
FMR LLC
2,423,213US$38.9m-15%no data
4.04%
Schooner Century Fund Llc
1,047,594US$16.8m0%no data
2.78%
MPM BioImpact LLC
721,139US$11.6m14.6%1.46%
2.55%
BlackRock, Inc.
659,402US$10.6m55.7%no data
2.21%
Invus Financial Advisors, LLC
572,236US$9.2m0%0.44%
1.66%
The Vanguard Group, Inc.
429,480US$6.9m76.7%no data
1.6%
HBM Partners Ltd.
415,234US$6.7m0.7%0.63%
1.48%
Thirsty Brook 2010 Irrevocable Trust
383,796US$6.2m0%no data
1.22%
Citadel Advisors LLC
315,000US$5.1m-16.2%no data
1%
Michael Singer
259,416US$4.2m0.77%no data
0.96%
JP Morgan Asset Management
248,313US$4.0m-12.5%no data
0.85%
Geode Capital Management, LLC
221,257US$3.6m63.1%no data
0.67%
Erste Asset Management GmbH
173,566US$2.8m0%0.02%
0.67%
State Street Global Advisors, Inc.
172,620US$2.8m9.6%no data
0.48%
683 Capital Management, LLC
125,000US$2.0m65.7%0.2%
0.37%
Northern Trust Global Investments
95,030US$1.5m50.6%no data
0.3%
Baharak Asefzadeh
78,634US$1.3m0%no data
0.28%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
72,099US$1.2m198%no data
0.2%
Ikarian Capital, LLC
52,166US$837.3k-0.05%0.26%
0.12%
Carsten Brunn
30,244US$485.4k246%no data
0.11%
Goldman Sachs Group, Investment Banking and Securities Investments
27,525US$441.8k143%no data
0.1%
Chris Jewell
26,928US$432.2k92.3%no data
0.1%
Charles Schwab Investment Management, Inc.
26,803US$430.2k40.7%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/23 01:39
End of Day Share Price 2025/03/21 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cartesian Therapeutics, Inc. is covered by 9 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Julian HarrisonBTIG
John NewmanCanaccord Genuity
Kristen KluskaCantor Fitzgerald & Co.